Market Tracker

02/27 5:16pm ET

Alkermes Plc (NASDAQ:ALKS)

55.40
Delayed Data
As of Feb 27
 +2.42 / +4.57%
Today’s Change
27.14
Today|||52-Week Range
60.74
-0.32%
Year-to-Date
Who Is Winning the Fight Against Opioid Abuse?
Feb 27 / GuruFocus News - Paid Partner Content
Drug Addiction Treatment Stocks to Watch
Feb 22 / GuruFocus News - Paid Partner Content
J.P. Marvel Investment Advisors, LLC Buys Akamai Technologies, Zayo Group Holdings, A...
Feb 23 / GuruFocus News - Paid Partner Content
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
Feb 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close52.98
Today’s open53.06
Day’s range52.54 - 55.47
Volume1,352,735
Average volume (3 months)1,098,399
Market cap$8.1B
Dividend yield--
Data as of 3:59pm ET, 02/27/2017

Growth & Valuation

Earnings growth (last year)+9.21%
Earnings growth (this year)+344.37%
Earnings growth (next 5 years)+57.70%
Revenue growth (last year)+18.68%
P/E ratioNM
Price/Sales11.29
Price/Book6.68

Competitors

 Today’s
change
Today’s
% change
JAZZJazz Pharmaceuticals...+0.86+0.63%
RDYDr.Reddy's Laborator...+0.03+0.07%
SGENSeattle Genetics Inc+3.19+5.09%
UTHRUnited Therapeutics ...+5.80+3.95%
Data as of 4:02pm ET, 02/27/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.10
Annual revenue (last year)$745.7M
Annual profit (last year)-$208.4M
Net profit margin-27.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
President
Shane M. Cooke
Corporate headquarters
Dublin, Dublin

Forecasts